Dopa-responsive dystonia: pathological and biochemical observations in a case.
We report the first neuropathological and neurochemical study of a patient with dopa-responsive dystonia. She had onset of foot dystonia at age 5 years and by age 8 years it was generalized with prominent right leg and arm involvement. On levodopa 750 mg daily she had complete symptomatic improvement that was sustained for 11 years until death. Pathological studies revealed normal numbers of hypopigmented substantia nigra neurons, normal tyrosine hydroxylase (TH) immunoreactivity and TH protein in the SN, no inclusion bodies or gliosis, and no evidence of a degenerative process in the striatum. Biochemical studies revealed reduced dopamine in the substantia nigra and striatum (8% in the putamen and 18% of control in the caudate) with a similar but not identical subregional distribution as in idiopathic Parkinson's disease. In the striatum, TH protein and TH activity was reduced, with the loss more pronounced in the putamen than the caudate. The GBR 12935 binding to DA transporter was normal in the caudate and at the lower end of the range of control values in the putamen. We conclude that disturbed dopamine synthetic capacity or a reduced arborization of striatal dopamine terminals may be the major disturbance in dopa-responsive dystonia.
Rajput
A H
AH
University of Saskatchewan, Saskatoon, Canada.
Gibb
W R
WR
Zhong
X H
XH
Shannak
K S
KS
Kish
S
S
Chang
L G
LG
Hornykiewicz
O
O
D000328:Adult; D001921:Brain / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D002648:Child; D004298:Dopamine / Q000032:analysis; D004421:Dystonia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006719:Homovanillic Acid / Q000032:analysis; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D011869:Radioligand Assay; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D007980:Levodopa; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine; D006719:Homovanillic Acid